ArticleHepatology international2026
Outcomes of first and further decompensation events in advanced chronic liver disease: a multi-centre competing risks analysis.
Article in Hepatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond the Tipping Point: Advances in the Diagnosis and Management of Acute-on-Chronic Liver Failure and End-Stage Liver Disease.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsDecompensated cirrhosis carries a significant health burden with high mortality. The aim of this study was to assess incidence of further decompensation and survival in patients with cirrhosis following hospitalization with initial decompensation.
methodsAdult patients with cirrhosis at three Australian state-wide liver transplant centres from 2006 to 2025, admitted to hospital with a first decompensating event (ascites, hepatic encephalopathy, variceal bleeding) and followed until further decompensation requiring hospitalisation, liver-related death (LRD), non-liver related death, or liver transplant (LT).
resultsA total of 542 patients were followed from first decompensation for a median of 24 (IQR 9-48) months, with alcohol-related liver disease the most common etiology (52%). Cumulative incidence of further decompensation at 5-years was 65.1% (95% CI 60.3-69.5), and incidence of LRD or LT was 39.2% (95% CI 34.1-44.2). Following further decompensation, cumulative incidence of LRD or LT was higher compared to first decompensation at 55.5% (sHR 3.45, 95% CI 2.31-5.16, p < 0.001). Ascites was the most common type of further decompensation (35.6%, 95% CI 31-40.2). Etiological treatment of the underlying CLD was protective for further decompensation and LRD/LT (sub hazard ratio [sHR] 0.58 and 0.65 respectively, p < 0.05), as was treatment with a non-selective beta blocker (sHR 0.40 and 0.60, p < 0.01).
conclusionsThis multi-centre study describes the trajectory of patients after a first episode of decompensation for the first time in the Australian context. It highlights high morbidity and poor prognosis associated with further decompensation with over 50% dying or requiring LT within 5 years.
Indexed as
Identifiers
42014557What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.